A New Era in Medical Imaging

Real-time fusion of functional and anatomical images for interventional molecular imaging

CURRENT DIAGNOSIS CANCER LIMITATIONS

Uncertainties in cancer Biopsy

False Negatives & Positives

Tumor biopsy is the primary method for diagnosing cancer. However, current biopsies are guided solely by morphological images. This, along with difficulties in accessing certain tumors, intra-tumor heterogeneity, and changes in tumor genetic composition resulting from malignant neoplasms, contributes to high rates of false negatives and positives.

0 %

False Negatives

0 %

False positives (over 10 years)

0 %

False negatives

0 %

False Postives

EXCLUSIVE TECHNOLOGY

PET + ULTRASOUND HYBRID IMAGING

HYBRIMS' patented medical technology uniquely combines real-time metabolic information from PET images with morphological information obtained from ultrasound. This integration allows for precise guidance of the biopsy needle to target the most active or aggressive areas of the tumor. By combining these two types of information, our technology ensures accurate biopsy sampling of the most representative tumor and lymph node samples.

INTERVENTIONAL MOLECULAR IMAGING

COMPACT and PORTABLE IMAGING SYSTEM

MULTIMODAL FUSION IMAGING

BENEFITS

PRECISE CANCER BIOPSY

Real-time guidance to representative tumor samples

PET and ULTRASOUNDS hybrid real-time images resolve intra-tumor heterogeneity and permit physicians to guide the biopsy needle to sample the most representative tissues of the tumor and lymph nodes.

Mission, Vision & Values

Our Challenge

We aim to develop and globally commercialize medical devices that improve cancer diagnosis, with the goal of enhancing quality of life and reducing diagnostic errors worldwide. Making our technology accessible to patients is a key motivation, offering hope for improved recovery from serious diseases like cancer.

Create imaging technologies for the precise diagnosis and treatment of cancer facilitating personalized medicine to improve the clinical prognosis.

Develop, manufacture a market disruptive imaging technologies for the diagnosis and treatment of cancer, reducing times, improving reliability and precision.

Innovation, excellence, social commitment and satisfactorily responding to clinical needs in order to improve people's lives and quality life.

Tumor biopsy guided by molecular Imaging

Our exclusive technology allows for the first time the guidance of the cancer biopsy process based on images of the distribution of radioisotopes in the patient

MEET THE TEAM

About us

HYBRIMS is a spin-off company of the Spanish National Research Council (CSIC) and the University of Valencia, founded by a multidisciplinary team of leading researchers in medical imaging. Each member of our team is firmly committed to leveraging innovation to enhance patients' quality of life. By actively listening to clinicians' needs, we have developed hybrid imaging systems that surpass existing technologies, offering new tools in the battle against diseases like cancer. This dedication is our primary motivation.